Skip to main content

Table 1 Summary of chronic dialysis therapy in Japan, 2019

From: Annual dialysis data report 2019, JSDT Renal Data Registry

(a) Facility number and dialysis capacity

Facility number and dialysis capacity

Number

Changes from the previous year (%)

Surveyed faciliteis

4487

+ 29 (+ 0.7)

Responded facilities

4411

+ 9 (+ 0.2)

Dialysis capacity

Number of bedside machines

141,520

+ 1,633 (+ 1.2)

Capacity for simultaneous HD treatments

139,839

+ 1,684 (+ 1.2)

Maximum patient capacity

464,615

+ 6,018 (+ 1.3)

(b) Patient dynamics

Patient category

Number

Changes from the previous year (%)

Prevalent patients

344,640

+ 4799 (+ 1.4)

  Prevalence rate (per million of general population)

2731.6

+ 43.9 (+ 1.6)

  Patients in the night shift

32,027

+ 483 (+ 1.5)

Incident patients

40,885

+ 417 (+ 1.0)

  Started with HD or HDF

38,228

+ 53 (+ 0.1)

  Started with PD

2657

+ 364 (+ 15.9)

Deceased patients

34,642

+ 779 (2.3)

(c) Numbers of prevalent dialysis patients by modality

Modality

Outpatients (%)

Inpatients (%)

Total (%)

Hemodialysis

HD

163,900

(52.3)

23838

(75.6)

187,738

(54.5)

HDF

137,552

(43.9)

7134

(22.6)

144,686

(42.0)

HF

19

(0.0)

12

(0.0)

31

(0.0)

HAD

1425

(0.5)

80

(0.3)

1505

(0.4)

Home HD

754

(0.2)

6

(0.0)

760

(0.2)

Peritoneal dialysis (PD)

PD only

7647

(2.4)

370

(1.2)

8017

(2.3)

PD + HD 1x/week

1620

(0.5)

55

(0.2)

1675

(0.5)

PD + HD 2x/week

122

(0.0)

6

(0.0)

128

(0.0)

PD + HD 3x/week

24

(0.0)

6

(0.0)

30

(0.0)

PD + HD other frequencies

63

(0.0)

7

(0.0)

70

(0.0)

Subtotal

9476

(3.0)

444

(1.4)

9920

(2.9)

Total

313,126

(100.0)

(31,514)

(100.0))

344,640

(100.0))

  1. PD + HD patients: Patients treated by the combination of PD and HD, HDF, hemoadsorption, or hemofiltration (excluding those who underwent only peritoneal lavage)
  2. HD, hemodialysis; HDF, hemodiafiltration; HF, hemofiltration; HAD, hemoadsorption dialysis; PD, peritoneal dialysis
  3. HAD refers to hemodialysis therapy combined with hemoadsorption using a tandem-connected beta2- microglobulin adsorptive column
  4. *The data were obtained from the facility survey